First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants...
treatment News
REYKJAVIK, Iceland — Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). “The progress of our product pipeline clearly illustrates the advantage of our...
Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. The primary endpoint gauged the daily mean Area Under the Effect Curve (AUEC)...
STOCKHOLM, Sweden – AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) – AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer’s disease and pain, today announced it has received a positive response from the U.S. Food and Drug Administration (FDA) regarding the...
STOCKHOLM, SWEDEN –AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates for CNS diseases, focusing on Alzheimer’s disease and pain, today announced that another scientific article has been published on the phase I clinical results supporting the continued development of the...
Luxembourg – In a new position paper, and following engagement with its national members and the European Working Group of People with Dementia (EWGPWD), Alzheimer Europe calls for concrete actions to enable timely, safe and equitable access to anti-amyloid drugs, for patients who are most likely to benefit from these...
FRAMINGHAM, Mass. — Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced its participation in the Nobel Forum “Challenges for Implementation of New Alzheimer’s Disease Treatments” covering Alzheimer’s therapeutics for...
LILLE, France — ALZPROTECT is thrilled to announce that it has received favorable feedback from both the U.S. food and drug administration (FDA) and European Medicines Agency (EMA) regarding the regulatory path for advancing the clinical development of Ezeprogind/AZP2006 for patients with PSP. This significant milestone follows the already very...
DUBLIN — Amarin Corporation plc (NASDAQ:AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic autoimmune disease characterized by muscle weakness which can be life-threatening. Thomas Lynch, Chairman and Chief Executive Officer of Amarin,...
THOUSAND OAKS, Calif. — Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon, executive vice...